There are currently 687 clinical trials in Oklahoma City, Oklahoma looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Oklahoma Health Sciences Center, Mercy Hospital Oklahoma City, GSK Investigational Site and Lynn Health Science Institute. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Genotype and Phenotype Correlation in Hereditary Thrombotic Thrombocytopenic Purpura (Upshaw-Schulman Syndrome)
NCT01257269
Recruiting
Hereditary thrombotic thrombocytopenic purpura (Upshaw-Schulman syndrome) is a rare disorder characterized by thrombocytopenia as a result of platelet consumption, microangiopathic hemolytic anemia, occlusion of the microvasculature with von Willebrand factor-platelet-thrombic and ischemic end organ damage. The underlying patho-mechanism is a severe congenital ADAMTS13 (a disintegrin and metalloproteinase with thrombospondin type 1 motif, 13) deficiency which is the result of compound heterozygo... Read More
Gender:
ALL
Ages:
All
Trial Updated:
10/10/2023
Locations: University of Oklahoma Health Sciences Center, Department of Medicine, PO Box 26901, Oklahoma City, Oklahoma
Conditions: Thrombotic Thrombocytopenic Purpura, Congenital Thrombotic Thrombocytopenic Purpura, Familial Thrombotic Thrombocytopenic Purpura, Thrombotic Thrombocytopenic Purpura, Congenital, Upshaw-Schulman Syndrome
Register for Updates
CAN-Stim Compared to SNS in Treatment of Urinary Urgency Incontinence With Wireless Neuromodulation Technology
NCT02577302
Recruiting
This is a prospective, randomized, controlled, multi-center, study in which 150 evaluable subjects will be randomized 1:1 to receive either a Protect CAN-Stim or SNS InterStim® system. Subjects from both groups will immediately start with therapy. The primary endpoint is a ≥ 50% reduction in number of incontinence episodes associated with urgency at the 3-month visit, with additional measurements assessed at 14 days, 1, 6, 9 and 12-months.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
10/03/2023
Locations: University of Oklahoma health Sciences Center, Oklahoma City, Oklahoma
Conditions: Urinary Incontinence, Urge
Register for Updates
Post-Approval Study of the TREO Abdominal Stent-Graft System
NCT04697784
Recruiting
The purpose of this study is to determine the long-term performance of the TREO Abdominal Stent-Graft as a treatment for patients with Infrarenal Abdominal Aortic Aneurysms or Aorto-iliac Aneurysms.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/27/2023
Locations: Oklahoma University Health and VA Medical Center, Oklahoma City, Oklahoma
Conditions: Abdominal Aortic Aneurysm
Register for Updates
OPN-375 Efficacy and Safety in Adolescents With Bilateral Nasal Polyps
NCT03747458
Recruiting
This is a 16-Week Randomized, Double-Blind, Placebo Controlled, Parallel-Group, Multicenter Study Evaluating the Efficacy and Safety of OPN-375 186 μg Twice a Day (BID) in Adolescents with Bilateral Nasal Polyps followed by a 12-Week Open-Label Treatment Phase. The total planned number of subjects is approximately 120 adolescents (12-17 years of age) who will be randomly assigned to receive 1 of 2 study treatments using a 2:1 ratio (OPN-375 186 μg: Placebo). For the PK sub-study, up to 14 subjec... Read More
Gender:
ALL
Ages:
Between 12 years and 17 years
Trial Updated:
09/22/2023
Locations: Allergy, Asthma & Clinical Research Center, Oklahoma City, Oklahoma
Conditions: Bilateral Nasal Polyposis
Register for Updates
A Phase 1/2, Open-label, Multicenter, Dose Escalation and Expansion Study of SLC-3010 Monotherapy and in Combination
NCT05525247
Recruiting
This is a Phase 1/2, open-label, multicenter, dose escalation and expansion study, evaluating the safety, tolerability, pharmacokinetic, preliminary anti-tumor activity, and effects on pharmacodynamic markers following administration of SLC-3010 as monotherapy and in combination with gemcitabine, in patients with various advanced solid tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
09/18/2023
Locations: Selecxine Investigator site, Oklahoma City, Oklahoma
Conditions: Advanced Solid Tumor
Register for Updates
A Phase 3 Study to Investigate the Efficacy and Safety of SHR0302 With Moderately to Severely Active Ulcerative Colitis
NCT05181137
Recruiting
This is a randomized, double-blind, placebo-controlled, multicenter Phase 3 study that will enroll approximately 368 subjects aged 18 to 75 years old with Moderately to Severely Active Ulcerative Colitis.
Gender:
ALL
Ages:
Between 18 years and 75 years
Trial Updated:
09/01/2023
Locations: DDSI, Oklahoma City, Oklahoma +1 locations
Conditions: Ulcerative Colitis
Register for Updates
AltaValve Early Feasibility Study Protocol
NCT03997305
Recruiting
Prospective, single-arm, multicenter study to evaluate the safety and performance of the AltaValve for the treatment of moderate to severe or severe mitral valve regurgitation in subjects who are considered high risk for mortality and morbidity from conventional open-heart surgery.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
08/31/2023
Locations: Oklahoma Heart Hospital, Oklahoma City, Oklahoma
Conditions: Mitral Regurgitation, Mitral Insufficiency, Mitral Valve Incompetence, Mitral Valve Regurgitation, Mitral Incompetence
Register for Updates
Groningen International Study on Sentinel Nodes in Vulvar Cancer-III
NCT05076942
Recruiting
Vulvar cancer patients with SN-metastasis \> 2mm will receive chemoradiation instead of an inguinofemoral lymphadenectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
07/27/2023
Locations: University of Oklahoma Health Sciences Center, Oklahoma City, Oklahoma
Conditions: Vulvar Cancer, Sentinel Lymph Node, Lymph Node Metastases
Register for Updates
Study of Immune Globulin Intravenous (Human) GC5107 in Pediatric Subjects With Primary Humoral Immunodeficiency
NCT04565015
Recruiting
The purpose of this study is to evaluate the pharmacokinetics and safety of Immune Globulin Intravenous (Human) GC5107 in pediatric subjects with Primary Humoral Immunodeficiency (PHID).
Gender:
ALL
Ages:
Between 2 years and 16 years
Trial Updated:
05/15/2023
Locations: Oklahoma Institute of Allergy & Asthma Clinical Research, LLC, Oklahoma City, Oklahoma
Conditions: Primary Immune Deficiency
Register for Updates
Physica System Total Knee Replacement Registry Study
NCT03048201
Recruiting
The primary objective of this study is to obtain long-term implant survivorship (out to 10 years) and to assess clinical, patient-reported outcome measures, and radiographic data for the commercially available Physica system. For ancillary arm, from baseline to 5-year follow-up.
Gender:
ALL
Ages:
22 years and above
Trial Updated:
03/17/2023
Locations: Joint Reconstructive Specialist, Oklahoma City, Oklahoma
Conditions: Osteoarthritis, Knee, Traumatic Arthritis, Avascular Necrosis, Degenerative Joint Disease of Knee, Rheumatoid Arthritis, Deformity of Knee
Register for Updates
Study to Assess Allogeneic Anti-CD38 A2 Dimeric Antigen Receptor T Cells in Relapsed or Refractory Multiple Myeloma
NCT05007418
Recruiting
This is a phase 1b, open-label, dose-escalation study of STI-1492 administered by a single intravenous infusion in subjects with relapsed or refractory multiple myeloma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/12/2023
Locations: University of Oklahoma, Oklahoma City, Oklahoma
Conditions: Multiple Myeloma
Register for Updates
Proton and Photon Consortium Registry (PPCR): A Multi Center Registry of Pediatric Patients Treated With Radiation Therapy
NCT01696721
Recruiting
In previous studies, Proton Beam Radiation Therapy (PBRT) has been found to show better results in treating patients with cancer, both because there is better control of where in the body the radiation is directed and because it is associated with less severe long term side effects. However, there is limited published data demonstrating these results. The goal of the Proton and Photon Consortium Registry (PPCR) is to enroll children treated with radiation in order to describe the population that... Read More
Gender:
ALL
Ages:
21 years and below
Trial Updated:
01/05/2023
Locations: ProCure Proton Therapy Center- Oklahoma, Oklahoma City, Oklahoma
Conditions: Pediatric Patients Treated With Radiation Therapy
Register for Updates